But, in several tumors that normally lack IKZF1 expression, overexpression of Ikaros leads to enhanced immune recruitment infiltration and tumor sensitivity to CTLA4 and PD1 inhibitors (Chen et al., 2018). The gene discussed is CTLA4; the disease is neoplasm.